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ADAPTING FEDERAL REGULATORY APPROACHES TO
ADVANCES IN AGRICULTURAL BIOTECHNOLOGY
ALAN SACHS *
Since it was first announced by the White House Office of Science and
Technology Policy (“OSTP”) in 1986, the Coordinated Framework for the
Regulation of Biotechnology (“Framework”) has sought to achieve
“reasonable safeguards for the public” by regulating products of
biotechnology across a network of agency jurisdictions using existing federal
statutory authorities, as opposed to calling for the implementation of new
legislation. 1 Working to achieve a balance between appropriate health and
environmental safety regulations while maintaining sufficient flexibility to
“avoid impeding the growth” of what was considered an “infant industry” at
the time, the Framework was built on a foundational determination that the
existing mosaic of existing federal laws, as currently implemented, would for
the most part “adequately” address regulatory needs. 2
One of the key challenges associated with formulating any federal
approach to biotechnology regulation is the sheer diversity of products that
can be developed with genetic engineering—including agricultural crops and
livestock, pesticides, food, plants, human and animal drugs, and
microorganisms with a range of industrial applications. These products are
already regulated by a myriad of agencies, meaning a unitary statutory
approach addressing all products of biotechnology would be challenging. 3
More than three decades after the Framework was first announced—and
notwithstanding periodic controversy, 4 continued uneasiness with products
of genetic engineering among sectors of the American public, 5 as well as
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1. Coordinated Framework for Regulation of Biotechnology, 51 Fed. Reg. 23,302, 23,302
(June 26, 1986).
2. Id. at 23,303.
3. Although a number of federal agencies are involved in regulating products of
biotechnology, this discussion focuses on the Environmental Protection Agency (“EPA”), Food and
Drug Administration (“FDA”), and U.S. Department of Agriculture (“USDA”).
4. See, e.g., Biotechnology, Genetic Engineering, and “GMOs:” Why all the Controversy?,
INST. OF FOOD TECHNOLOGISTS (Sept. 12, 2018), https://www.ift.org/career-development/learnabout-food-science/food-facts/food-facts-emerging-science-and-technologies/biotechnologygenetic-engineering-gmos.
5. See CARY FUNK & BRIAN KENNEDY, THE NEW FOOD FIGHTS: U.S. PUBLIC DIVIDES OVER
FOOD SCIENCE, PEW RESEARCH CENTER 46 (2016), https://www.pewresearch.org/internet/wp-
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groundbreaking advances in biotechnology that could hardly have been
foreseen by the Framework’s authors in 1986—OSTP’s original decision to
balance regulation and flexibility within existing statutory authorities has
largely stood the test of time. Contemporary agency efforts to adapt
regulatory approaches to novel advances in agricultural biotechnology, while
remaining true to the Framework’s decades-old intent and design, bear this
out.
The Framework originally sought to cover the full spectrum of
biotechnology applications by assigning jurisdiction over the commercial
end-products of biotechnology based on each agency’s experience with the
review and regulation of similar products developed using conventional
techniques. For example, the U.S. Department of Agriculture (“USDA”)
would be responsible for genetically engineered animal biologics, plant pests,
seeds, animal pathogens, and meat, poultry, and eggs; 6 the U.S.
Environmental Protection Agency (“EPA”) was tasked with responsibility
over genetically engineered microbial pesticides and intergeneric
microorganisms; 7 and the U.S. Food and Drug Administration (“FDA”) was
assigned oversight for genetically engineered foods, food additives, human
drugs, biologics and devices, and animal drugs. 8 In developing their
coordinated but specific biotechnology regulatory programs, each agency
was able to rely on authorities prescribed by an array of existing
environmental laws and other statutes, including the Federal Plant Pest Act
(superseded in 2000 by the Plant Protection Act (“PPA”)); 9 the Federal Seed
Act (“FSA”); 10 the Federal Insecticide, Fungicide, and Rodenticide Act
(“FIFRA”); 11 the Federal Food, Drug, and Cosmetic Act (“FFDCA”); 12 the

content/uploads/sites/9/2016/11/PS_2016.12.01_Food-Science_FINAL.pdf (finding that 39% of
Americans believe genetically modified food is harmful to consume).
WEBSITE
FOR
BIOTECHNOLOGY
REGUL.,
6. USDA’s
Role,
UNIFIED
https://usbiotechnologyregulation.mrp.usda.gov/biotechnologygov/about (last visited Feb. 11,
2021).
WEBSITE
FOR
BIOTECHNOLOGY
REGUL.,
7. EPA’s
Role,
UNIFIED
https://usbiotechnologyregulation.mrp.usda.gov/biotechnologygov/about (last visited Feb. 11,
2021).
WEBSITE
FOR
BIOTECHNOLOGY
REGUL.,
8. FDA’s
Role,
UNIFIED
https://usbiotechnologyregulation.mrp.usda.gov/biotechnologygov/about (last visited Feb. 11,
2021).
9. Federal Plant Pest Act, Pub. L. No. 85-36, 71 Stat. 31 (1957), repealed by Agriculture Risk
Protection Act of 2000, Pub. L. No. 106-224, 114 Stat. 358.
10. Federal Seed Act, 7 U.S.C. §§ 1551–1611.
11. Federal Insecticide, Fungicide, and Rodenticide Act, 7 U.S.C. §§ 136–136y.
12. Federal Food, Drug, and Cosmetic Act, 21 U.S.C. §§ 301–399i.
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Toxic Substances Control Act (“TSCA”); 13 the Federal Meat Inspection Act
(“FMIA”); 14 and the Poultry Products Inspection Act (“PPIA”). 15
In 1992, OSTP released an update to the Framework reaffirming that
federal oversight “focuses on the characteristics of the biotechnology product
and the environment into which it is being introduced, not the process by
which the product is created” and clarifying that the “[e]xercise of oversight
in the scope of discretion afforded by statute should be based on the risk
posed by the introduction and should not turn on the fact that [a
biotechnology product] has been modified by a particular process or
technique.” 16 OSTP’s continued emphasis on the evaluation of each endproduct of agricultural biotechnology, irrespective of the genetic engineering
process used in its development, has proved remarkably resilient even as
scientific advancements over the last thirty years have progressed from
introducing recombinant DNA (“rDNA”) molecules through almost
exclusive reliance on bacterial vectors (frequently plant pest organisms
themselves) to, within just the last few years, the widespread use of
revolutionary genome editing techniques like Clustered Regularly
Interspaced Short Palindromic Repeats (“CRISPR”) that allow developers to
target specific genome mutations by inserting, deleting, or modifying DNA
in living organisms. 17
In 2017, OSTP published a second update to the Framework. While
concluding that the current federal regulatory system for the products of
biotechnology “effectively protects health and the environment,” OSTP also
observed that certain unnecessary costs and burdens associated with
uncertainty about agency jurisdiction, lack of predictability of timeframes for
review, and other processes limit the ability of technology developers to
successfully navigate the regulatory process. 18 The 2017 update also
acknowledged that regulatory complexities hamper the public’s ability to
easily understand how the safety of these products is assured. 19
Consistent with a number of key recommendations expressed in the
2017 update, federal agencies have undertaken significant actions in recent
13. Toxic Substances Control Act, 15 U.S.C. §§ 2601–2629.
14. Federal Meat Inspection Act, 21 U.S.C. §§ 601–695.
15. Poultry Products Inspection Act, 21 U.S.C. §§ 451–472.
16. Exercise of Federal Oversight Within Scope of Statutory Authority: Planned Introductions
of Biotechnology Products Into the Environment, 57 Fed. Reg. 6753, 6753 (Feb. 27, 1992).
17. What is CRISPR?, JACKSON LAB’Y, https://www.jax.org/personalized-medicine/precisionmedicine-and-you/what-is-crispr# (last visited Feb. 12, 2021).
18. OFF. OF SCI. & TECH. POL’Y, WHITE HOUSE, MODERNIZING THE REGULATORY SYSTEM
FOR BIOTECHNOLOGY PRODUCTS: FINAL VERSION OF THE 2017 UPDATE TO THE COORDINATED
FRAMEWORK
FOR
THE
REGULATION
OF
BIOTECHNOLOGY
1,
5
(2017),
https://www.epa.gov/sites/production/files/201701/documents/2017_coordinated_framework_update.pdf.
19. Id.
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years to clarify their respective roles, processes, and procedures under the
Framework. These efforts have included USDA’s statement that it does not
regulate plants developed with genome-editing techniques (as long as they
are developed without the use of a plant pest as the donor or vector, and they
are not themselves plant pests); 20 and FDA’s commitment to develop
guidance explaining how its current regulatory policy for foods derived from
new plant varieties applies to foods produced using genome editing. 21 In
May 2020, USDA established comprehensive new regulations, known as the
“SECURE rule,” that represent an overhaul of longstanding regulatory
requirements for genetically engineered organisms that pose plant pest
risks. 22
Efforts sparked by the 2017 update are ongoing. Recently, EPA
proposed new regulations to exempt certain plant-produced substances
developed using biotechnology (known as “plant-incorporated protectants,”
or “PIPs”) from FIFRA and FFDCA requirements if those substances are
otherwise found in plants that are sexually compatible with the recipient plant
and meet certain other criteria. 23 Additional initiatives, such as EPA, FDA,
and USDA’s joint publication of a new “Unified Website for Biotechnology
Regulation,” reflect broader federal efforts to improve transparency and
reduce uncertainty for the regulated community and the wider American
public. 24
Although science never remains static and future advances in genetic
engineering will undoubtedly press agricultural biotechnology techniques to
ever-expanding frontiers, agency regulations are necessarily framed around
an understanding of commercially viable techniques in existence at a
particular moment in time. Even so, the Framework’s regulation-by-product
approach has, for over thirty years, provided federal agencies with flexibility
to adapt their respective regulatory programs under existing environmental
statutory authorities to address scientific innovations as well as ongoing
developments in the understanding of potential risks.

20. Press Release, U.S. Dep’t of Agric., Secretary Perdue Issues USDA Statement on Plant
Breeding
Innovation
(Mar.
28,
2017),
https://www.usda.gov/media/pressreleases/2018/03/28/secretary-perdue-issues-usda-statement-plant-breeding-innovation.
21. U.S. FOOD & DRUG ADMIN., PLANT AND ANIMAL BIOTECHNOLOGY INNOVATION ACTION
PLAN 1–3 (2018), https://www.fda.gov/media/119882/download.
22. Movement of Certain Genetically Engineered Organisms, 85 Fed. Reg. 29,790, 29,791 n.3
(May 18, 2020) (codified at 7 C.F.R. pt. 330, 340, 372).
23. Pesticides; Exemptions of Certain Plant-Incorporated Protectants (PIPs) Derived From
Newer Technologies, 85 Fed. Reg. 64,308, 64,308 (proposed Oct. 9, 2020) (to be codified at 40
C.F.R. pt. 174).
24. About the Coordinated Framework, UNIFIED WEBSITE FOR BIOTECHNOLOGY REGUL.,
https://usbiotechnologyregulation.mrp.usda.gov/biotechnologygov/about (last visited Feb. 12,
2021).
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Operating within the Framework, regulatory agencies have the ability to
continuously reinforce their commitments to regulatory certainty and health
and environmental safety, all of which are necessary to support industry
innovation and consumer confidence in biotechnology-derived products.
Looking ahead, there may be growing importance attached to this
fundamental aspect of the Framework’s approach, which encourages regular
review and, as appropriate, updating agency policies and requirements to
adapt to advances in biotechnology and management of associated risks.

